EGFR and non-small cell lung carcinoma: On the contrary, the outcomes of adjuvant pembrolizumab are not comparable in terms of the magnitude of clinical benefit with those of adjuvant osimertinib, making its utilization synergistic with adjuvant chemotherapy and thus reinforcing the role of adjuvant chemotherapy in EGFR WT resected NSCLC (Table 2).